Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | 12/31/2022 | 09/30/2022 | |||
|---|---|---|---|---|---|
| Net Income | -- | -- | -20.34% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -- | -- | 61.37% | ||
| Change in Net Operating Assets | -- | -- | -217.33% | ||
| Cash from Operations | -- | -- | -26.53% | ||
| Capital Expenditure | -- | -- | -7.23% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -83.33% | ||
| Cash from Investing | -- | -- | -14.29% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | 5.61% | ||
| Issuance of Common Stock | -- | -- | -28.57% | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | 39.37% | ||
| Cash from Financing | -- | -- | 56.33% | ||
| Foreign Exchange rate Adjustments | -- | -- | -3.90% | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -- | -- | -20.17% | ||